VERSION 1 -REVIEW
The laboratory examinations included no glycaemia that is one of the most important CV risk factors. Moreover, as expected, compared to controls, the CAD patients exhibited had a higher incidence of conventional cardiovascular risk factors, which included higher SBP, DBP and BMI; higher levels of plasma total cholesterol, TG, and LDL-C but lower plasma levels of HDL-C. Diabetes should be included in this comparison or added in the study limitations section. Cardiovasc Genet. 2016 Dec;9(6):521-530) Authors cannot be sure that there is not any influence from other genotypes. It should discussed in general and added in the study limitations section. 
REVIEWER

GENERAL COMMENTS
You et al. studied the effects of three APOA5 polymorphisms in on plasma triglycerides (TG) level and and risk of coronary heart disease (CAD) in a Chinese HanPopulation, using a case-control study with 710 subjects (355 CAD patients and 355 controls). The authors showed that 2 APOA5 variants (rs662799 and rs651821) are associated to TG level and CAD in this population.
MAJOR COMMENTARIES 1. The study presents several methodological concerns.
-The case with CAD are well defined but the authors don't precise the selection of control. Are the controls matched for age, sex ? -The name of polymorphisms studied are not clear. The authors used different name for the same polymorphisms. They introduced 3 polymorphisms APOA5 c.-1131T>C, c-3A>G and S19W. It should be noted that c.C56C>G is the same polymorphism than S19W ! Then during the study, they studied 3 polymorphisms named by their rs number without correspondence with the previous name which is confusing. In fact, APOA5 rs662799 correspond -1131 T>C, rs651821 to -3A>G, rs2075291 to G185C.
-the choice of the three polymorphisms is not clear. The authors don't explain the choice of the rs2075291 / G185C variant. Moreover, it is known that the 2 variants APOA5 rs662799 ( -1131 T>C) and rs651821 (-3A>G) tagged the same APOA5 haplotype usually named APOA5*2 in the literature (haplotype 3 here). The authors clearly showed that they are in strong linkage disequilibrium in their haplotype study.
-how the authors explain that both APOA5 rs662799 and rs651821 are associated to CAD but not the haplotype with the 2 variants combined ? -The DNA reference sequence are not the same for the polymorphisms rs662799 and rs651821. The rs651821 is a T>C variant in the study and should be a A>G variant if you used the same reference sequence as for rs 662799 T>C variant. The nomenclature should be entirely revised using HGVS nomenclature. The term "polymorphism" should be replace by genetic "variants".
Results
This study only reproduced results already published with no new data in a small population. They argue discrepancies about the results in literature. In fact, the association of APOA5 rs662799 variant with TG and CAD is largely demonstrated in numerous studies of various ethnic origins including Chinese population and were confirmed in large meta-analysis. The rs2075291 have also been associated with TG in Asian populations (see review oh Hubacek Gene 2016). The rs651821 has been less studied as shown to be in strong linkage disequilibrium rs662799 and tag the same haplotype. Conversely, the discussion is incomplete. Moreover, no data about functional hypothesis of these polymorphisms are presented. A recent paper suggested involvement of miRNA (Caussy et al. Human molecular genetics 2014).
VERSION 1 -AUTHOR RESPONSE
Reviewers' Comments to Author: Reviewer: 1 1. The inclusion criteria for the healthy subjects were no history of MI and no evidence of MI on echocardiogram: I have some concern with the choice to not use any stress or perfusion test in order to exclude subclinical CAD. The research is looking for correlations between SNPs and myocardial ischemia. As we know, the latter is a complex disease that has a complex and not fully understood pathophysiological continuum starting classically from risk factors to myocardial ischemia until myocardial infarction. By echocardiography we can exclude only a few part of this continuum: only patients with MI with a visible myocardial wall dys-/a-kinesia. We know that we can have MI with preserved global and regional wall motion, moreover Authors aims to exclude patients with CAD that can be present with no symptoms and with no infarction and then undetectable by echocardiography but only at stress ECG or Echo test or perfusion test or invasive tests. This should be discussed and added in the study limitations section An: Thanks for your comment, in our study, all controls were no history of MI and no evidence of MI on echocardiogram. Individuals with any history or diagnoses of vascular disease, cancer, liver disease, renal disease, thyroid disease, or acute or chronic inflammatory disease were excluded. So this is our study,s limitation about definition of health people, now we have added in the study limitations section and all revision context are highlighted by using coloured text. (page 13 ) 2. The laboratory examinations included no glycaemia that is one of the most important CV risk factors. Moreover, as expected, compared to controls, the CAD patients exhibited had a higher incidence of conventional cardiovascular risk factors, which included higher SBP, DBP and BMI; higher levels of plasma total cholesterol, TG, and LDL-C but lower plasma levels of HDL-C. Diabetes should be included in this comparison or added in the study limitations section. An: Thanks for your comment, in our study, we only have figures for fasting blood glucose, so we added this limit in the study limitation section. (page13) Reviewer: 3 1. The study presents several methodological concerns. 1.1 The case with CAD are well defined but the authors don't precise the selection of control. Are the controls matched for age, sex? An: Our study is a case-control study, all subjects from a cross-sectional study which was conducted from June 2012 to August 2012; a total of 21,435 inhabitants in Jilin Province aged between 18 and 79 years were selected randomly based on multistage, stratified cluster sampling. In our study 355 Han Chinese individual with CAD were all from this survey termed as cases, 355 subjects who without CAD were random selected from this survey who are all health people as controls. All cases and controls were matched for age, however, because the prevalence rate of CAD is different in male and female, so our cases and controls are not matched for sex, considering this situation, we adjusted for sex in our all results.
1.2 The name of polymorphisms studied are not clear. The authors used different name for the same polymorphisms. They introduced 3 polymorphisms APOA5 c.-1131T>C, c-3A>G and S19W. It should be noted that c.C56C>G is the same polymorphism than S19W! Then during the study, they studied 3 polymorphisms named by their rs number without correspondence with the previous name which is confusing. In fact, APOA5 rs662799 correspond -1131 T>C, rs651821 to -3A>G, rs2075291 to G185C. An: Thanks a lot for your reminder, considering 3 polymorphisms named by their rs number which may causes confusing, we have used rs662799 replaced -1131 T>C, used rs651821 replaced -3A>G and used rs2075291 replaced G185C.
1.3 the choice of the three polymorphisms is not clear. The authors don't explain the choice of the rs2075291 / G185C variant. Moreover, it is known that the 2 variants APOA5 rs662799 (-1131 T>C) and rs651821 (-3A>G) tagged the same APOA5 haplotype usually named APOA5*2 in the literature (haplotype 3 here). The authors clearly showed that they are in strong linkage disequilibrium in their haplotype study. An: By 2012 this study was designed to evaluate the prevalence and risk factors associated with chronic diseases. We all known that Jilin is a special province because of the special weather, geographical location and eating habits, many the prevalence rate of chronic diseases are so high, including CAD, Metabolic Syndrome and so on. However, there is no research on associations between APOA5 genotypes and CAD in Jilin, Northeast China and we research many literatures find that the association between APOA5 polymorphisms rs662799, rs651821 and CAD is inconsistent, more importantly, there is no study about association between APOA5 polymorphisms rs2075291 and CAD in Jilin, Northeast China. So we did this study that explore the association between single nucleotide polymorphisms in the APOA5 and CAD. In addition, according to our database, rs662799 and rs651821 are not tag SNPs (we mentioned at Materials and methods>> SNP selection) in our subjects.
1.4 how the authors explain that both APOA5 rs662799 and rs651821 are associated to CAD but not the haplotype with the 2 variants combined ? An: Thanks a lot for your reminder, because our manuscript was sent to embellish, during this period, we did not check the figures carefully after the manuscript returned. Now, we have revised the data and all revision context are highlighted by using coloured text. (page13) 1.5 The DNA reference sequence are not the same for the polymorphisms rs662799 and rs651821. The rs651821 is a T>C variant in the study and should be a A>G variant if you used the same reference sequence as for rs662799 T>C variant. An: Thanks a lot for your reminder, we have checked all DNA reference and changed the correct reference sequence (rs651821 is A>G and rs662799 is T>C).
2. Results 2.1 This study only reproduced results already published with no new data in a small population. They argue discrepancies about the results in literature. In fact, the association of APOA5 rs662799 variant with TG and CAD is largely demonstrated in numerous studies of various ethnic origins including Chinese population and were confirmed in large meta-analysis. The rs2075291 have also been associated with TG in Asian populations (see review oh Hubacek Gene 2016). The rs651821 has been less studied as shown to be in strong linkage disequilibrium rs662799 and tag the same haplotype. Conversely, the discussion is incomplete. Moreover, no data about functional hypothesis of these polymorphisms are presented. A recent paper suggested involvement of miRNA (Caussy et al. Human molecular genetics 2014). An: Thanks a lot for your comments, the small samples are our study,s limitation, so we added it in our study,s limitation, and another studies of various ethnic origins are valuable, considering that there is no research on the association APOA5 with CAD in Jilin, Northeast China. So, we decided to study it. The rs662799 and rs651821 are not tag SNPs in our subjects. In addition, regarding involvement of miRNA, we have read this paper (Caussy et al. Human molecular genetics 2014) which is valuable, so we added this paper in our study,s discussion section and have revised our discussion section. 
GENERAL COMMENTS
The authors correctely responded to all major points of the review and corrected their manuscpript according to the previous recommendations (justification of the SNPs, methods, SNP numbers, limits and points of discussion ...). The revised manuscript now appears suitable for publication.
VERSION 2 -AUTHOR RESPONSE
Reviewer: 1 1. The inclusion criteria for the healthy subjects were no history of MI and no evidence of MI on echocardiogram: I have some concern with the choice to not use any stress or perfusion test in order to exclude subclinical CAD. The research is looking for correlations between SNPs and myocardial ischemia. As we know, the latter is a complex disease that has a complex and not fully understood pathophysiological continuum starting classically from risk factors to myocardial ischemia until myocardial infarction. By echocardiography we can exclude only a few part of this continuum: only patients with MI with a visible myocardial wall dys-/a-kinesia. We know that we can have MI with preserved global and regional wall motion, moreover Authors aims to exclude patients with CAD that can be present with no symptoms and with no infarction and then undetectable by echocardiography but only at stress ECG or Echo test or perfusion test or invasive tests. This should be discussed and added in the study limitations section. (We can't see where the limitations sub-section of the discussion has been revised to address reviewer 1's concern below. Can you please provide the relevant extract in your next rebuttal letter?)
An: Thanks for your comment, this is our study,s limitation about definition of health people, now we have added in the study limitations section and all revision context are highlighted by using coloured text. The detailed context is: CAD is a complex disease with a complex pathophysiology caused by interactions between multiple endogenous and exogenous factors. Many diagnostic criteria for CAD have been reported. In our study, all healthy subjects had no history of MI and no evidence of MI on an echocardiogram, but this method may not exclude potential patients with CAD who are asymptomatic and did not experience an infarction. Therefore, in future studies, subjects without CAD should be chosen using stricter criteria.
